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Alzheimer's disease (AD) has been ranked as the most dangerous and prevalent 
neurodegenerative disease worldwide accompanied by the absence of a fully effective anti-
AD medication tightly due to the presence of the blood-brain barrier (BBB). Nose-to-Brain 
delivery enhances the ability of some drugs to bypass the BBB achieving a therapeutic 
concentration directly in the brain especially for those with low brain concentrations after a 
routine delivery. Since the inflammatory process is involved in the pathogenesis of AD and the 
association of meloxicam with antioxidant properties, the latter could be used in AD 
management. Unfortunately, poor permeability across the BBB limits its use for the treatment 
of neurodegenerative disorders in addition to the high rate of plasma protein binding and low 
apparent distribution volumes.  Encapsulation of meloxicam in lipid based nanocarriers, 
particularly solid lipid nanoparticles (SLN) could be promising for nose to brain delivery due to 
their biocompatibility, protecting the therapeutic load, while improving its interaction with 
the olfactory regions. 
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